University Medical Center Freiburg-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2023

  1. Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma: Final Data from the Phase 2 ELOQUENT-3 Trial

    HemaSphere, Vol. 7, Núm. 3, pp. E843

  2. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

    The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269

2021

  1. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

    The Lancet Haematology, Vol. 8, Núm. 12, pp. e934-e946

  2. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

    Leukemia, Vol. 35, Núm. 6, pp. 1722-1731

  3. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

    Blood Cancer Journal, Vol. 11, Núm. 12

2017

  1. Is immunotherapy here to stay in multiple myeloma?

    Haematologica, Vol. 102, Núm. 3, pp. 423-432

  2. Prevention and management of adverse events of Novel agents in multiple myeloma: A consensus of the European myeloma network

    Leukemia, Vol. 2017

  3. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

    The Lancet Oncology, Vol. 18, Núm. 4, pp. e206-e217